Analysts Expect Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Will Announce Earnings of -$0.22 Per Share

Analysts expect Sol-Gel Technologies Ltd. (NASDAQ:SLGLGet Rating) to post ($0.22) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Sol-Gel Technologies’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.20). Sol-Gel Technologies reported earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Sol-Gel Technologies will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.30). For the next financial year, analysts expect that the company will report earnings of ($0.34) per share, with EPS estimates ranging from ($0.52) to ($0.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Sol-Gel Technologies.

Sol-Gel Technologies (NASDAQ:SLGLGet Rating) last announced its earnings results on Wednesday, March 30th. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.21. Sol-Gel Technologies had a net margin of 10.30% and a return on equity of 7.03%.

A number of brokerages have weighed in on SLGL. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Sol-Gel Technologies in a research note on Thursday, December 23rd. Zacks Investment Research raised shares of Sol-Gel Technologies from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Wednesday, April 6th. Finally, Raymond James reduced their price target on shares of Sol-Gel Technologies from $21.00 to $17.00 and set a “strong-buy” rating for the company in a research report on Friday, April 1st.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Susquehanna International Group LLP grew its position in Sol-Gel Technologies by 34.0% in the 4th quarter. Susquehanna International Group LLP now owns 16,862 shares of the company’s stock worth $125,000 after purchasing an additional 4,275 shares during the period. Raymond James & Associates grew its position in Sol-Gel Technologies by 14.1% in the 3rd quarter. Raymond James & Associates now owns 36,608 shares of the company’s stock worth $365,000 after purchasing an additional 4,519 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in Sol-Gel Technologies by 6.2% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 129,011 shares of the company’s stock worth $1,288,000 after purchasing an additional 7,544 shares during the period. Finally, We Are One Seven LLC bought a new stake in Sol-Gel Technologies in the 4th quarter worth approximately $74,000. 28.79% of the stock is owned by institutional investors.

Shares of NASDAQ SLGL traded up $0.65 on Friday, reaching $7.19. 24,897 shares of the company’s stock traded hands, compared to its average volume of 13,468. Sol-Gel Technologies has a 12 month low of $6.12 and a 12 month high of $15.31. The business’s 50 day simple moving average is $7.36 and its two-hundred day simple moving average is $7.84.

About Sol-Gel Technologies (Get Rating)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.

Recommended Stories

Get a free copy of the Zacks research report on Sol-Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.